Although about 10-20% of breast cancers are triple negative, it would be of interest to study CD74 and CD44 in a cohort of breast cancer cells tested negative for estrogen receptors, progesterone receptor, and HER2. This evidence concerns the gene ERBB2 and breast cancer.